Eledon pharmaceuticals reports first quarter 2025 operating and financial results

On track to report topline results from phase 2 bestow trial in kidney transplantation in fourth quarter of 2025 tegoprubart used as a key component of immunosuppression regimen in its second transplant of a genetically modified pig kidney into a human conducted at massachusetts general hospital cash, cash equivalents and short-term investments of $124.9 million as of march 31, 2025 irvine, calif., may 14, 2025 (globe newswire) -- eledon pharmaceuticals, inc. (“eledon”) (nasdaq: eldn) today reported its first quarter 2025 operating and financial results and reviewed recent business highlights.
ELDN Ratings Summary
ELDN Quant Ranking